Trial Profile
Clinical Efficacy of Remicade in Chronic Beryllium Disease: A Randomized, Double-Blind, Placebo-Controlled, Investigator Initiated Trial.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Pneumoconiosis
- Focus Therapeutic Use
- Acronyms BISCIT
- 24 Sep 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 18 Feb 2009 New trial record